Literature DB >> 30573188

Imaging Metabolic Processes to Predict Radiation Responses.

Sarwat Naz1, Shun Kishimoto2, James B Mitchell2, Murali C Krishna2.   

Abstract

The aberrant vasculature in the tumor microenvironment creates hypoxic zones, poor perfusion, and high interstitial fluid pressure. Also, the tumor cell metabolic phenotype utilizes the aerobic glycolytic pathways for energy source and generation of cell mass. These physiologic and metabolic phenotypes in solid tumors are amenable for molecular imaging techniques to extract imaging biomarkers such as pO2 and enzyme kinetics reflecting glycolysis. The imaging biomarkers have value in diagnostic and prognostic purposes. Additionally, they can be used to guide choices for tailored treatment regimens. Electron paramagnetic resonance imaging for pO2 imaging and 13C magnetic resonance imaging with hyperpolarized 13C probes such as 13C-labeled pyruvate have shown significant potential in characterizing the tumor microenvironment physiologically and metabolically.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30573188      PMCID: PMC6333210          DOI: 10.1016/j.semradonc.2018.10.004

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  26 in total

1.  Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck.

Authors:  D M Brizel; G S Sibley; L R Prosnitz; R L Scher; M W Dewhirst
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-05-01       Impact factor: 7.038

Review 2.  Brick by brick: metabolism and tumor cell growth.

Authors:  Ralph J Deberardinis; Nabil Sayed; Dara Ditsworth; Craig B Thompson
Journal:  Curr Opin Genet Dev       Date:  2008-04-02       Impact factor: 5.578

3.  Metabolic and Physiologic Imaging Biomarkers of the Tumor Microenvironment Predict Treatment Outcome with Radiation or a Hypoxia-Activated Prodrug in Mice.

Authors:  Shingo Matsumoto; Shun Kishimoto; Keita Saito; Yoichi Takakusagi; Jeeva P Munasinghe; Nallathamby Devasahayam; Charles P Hart; Robert J Gillies; James B Mitchell; Murali C Krishna
Journal:  Cancer Res       Date:  2018-05-23       Impact factor: 12.701

4.  A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.

Authors:  Ivraym B Barsoum; Chelsea A Smallwood; D Robert Siemens; Charles H Graham
Journal:  Cancer Res       Date:  2013-12-13       Impact factor: 12.701

Review 5.  Molecular pathways: hypoxia response in immune cells fighting or promoting cancer.

Authors:  Asis Palazón; Julián Aragonés; Aizea Morales-Kastresana; Manuel Ortiz de Landázuri; Ignacio Melero
Journal:  Clin Cancer Res       Date:  2011-12-28       Impact factor: 12.531

6.  Noninvasive in vivo oximetric imaging by radiofrequency FT EPR.

Authors:  Sankaran Subramanian; Ken-Ichi Yamada; Akira Irie; Ramachandran Murugesan; John A Cook; Nallathamby Devasahayam; Gootzian M Van Dam; James B Mitchell; Murali C Krishna
Journal:  Magn Reson Med       Date:  2002-05       Impact factor: 4.668

7.  Tumor hypoxia in cancer therapy.

Authors:  J Martin Brown
Journal:  Methods Enzymol       Date:  2007       Impact factor: 1.600

Review 8.  Understanding the Warburg effect: the metabolic requirements of cell proliferation.

Authors:  Matthew G Vander Heiden; Lewis C Cantley; Craig B Thompson
Journal:  Science       Date:  2009-05-22       Impact factor: 47.728

Review 9.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

10.  Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302.

Authors:  Yoichi Takakusagi; Shingo Matsumoto; Keita Saito; Masayuki Matsuo; Shun Kishimoto; Jonathan W Wojtkowiak; William DeGraff; Aparna H Kesarwala; Rajani Choudhuri; Nallathamby Devasahayam; Sankaran Subramanian; Jeeva P Munasinghe; Robert J Gillies; James B Mitchell; Charles P Hart; Murali C Krishna
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.